Wave Life Sciences Gains Buy Rating from Andrew Fein Amid Promising Trial Advancements and Potential Accelerated Approval Pathways
Wave Life Sciences (WVE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew ...
clinicaltrialsarena8h
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, ...
Business Insider20h
Erasca’s Innovative Naporafenib Shows Promise in NRAS-mutant Melanoma, Garnering Buy Rating from Analyst
Maldonado has given his Buy rating due to a combination of factors related to Erasca’s innovative approach in treating NRAS-mutant melanoma ... By upgrading to TipRanks Premium, you will gain access ...